SCHEMBL9629198

SCHEMBL9629198

CC1Cc2c(c3cccnc3n(-c3cccc(NS(C)(=O)=O)c3)c2=O)O1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 3/20 0.38
MET P08581 2/20 0.37
PIK3CD O00329 1/20 0.35
PIK3R2 O00459 1/20 0.35
PIK3CG P48736 1/20 0.35
BRD4 O60885 4/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
TGFBR1 P36897 1/20 0.35
NCOA1 Q15788 1/20 0.35
CYP1A2 P05177 2/20 0.33
ALDH1A1 P00352 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA1A P35348 1/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10659535 0.86 TNF (0.39) METBRD4PDE4APDE4BPDE4C
SCHEMBL9628976 0.85 MET (0.39) TDP2METPIK3CDPIK3R2PIK3CG
SCHEMBL9630898 0.83 HPGD (0.49) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL9629733 0.83 MET (0.39) TDP2METPIK3CDPIK3R2PIK3CG
SCHEMBL9629927 0.82 PDE4A (0.48) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL9629788 0.82 KAT2B (0.45) PDE4BPDE4DALDH1A1MAPTHPGD
SCHEMBL10739188 0.81 PDE4B (0.43) PDE4APDE4BPDE4CPDE4DCYP1A2
SCHEMBL10733706 0.81 PARP1 (0.37) TDP2METPIK3CDPIK3R2PIK3CG
SCHEMBL10654514 0.80 PDE4B (0.42) PDE4BPDE4DCYP1A2ALDH1A1MAPT
SCHEMBL10656123 0.79 PDE4A (0.35) BRD4PDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0338010-B1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1992-02-05 EP claimed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP claimed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP claimed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO claimed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP claimed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO claimed
EP-0127135-B1 FUSED TRICYCLIC DERIVATIVES OF NAPHTHYRIDINONE AND PYRIDONE AND THE CORRESPONDING THIONES SCHERING CORPORATION (US) 1990-08-29 EP disclosed
EP-0228416-B1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1990-03-21 EP disclosed
EP-0338010-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE. SCHERING CORP (US) 1989-10-25 EP disclosed
US-4801589-A QUINOLINE, NAPHTHYRIDINE, AND PYRIDO-PYRAZINE DERIVATIVES SCHERING CORPORATION (US) 1989-01-31 US disclosed
WO-1988004172-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF HYPERPROLIFERATE SKIN DISEASE SCHERING CORPORATION (US) 1988-06-16 WO disclosed
US-4740511-A ANTIALLERGENS, ANTIINFLAMMATORY, ANTIULCER AGENTS SCHERING CORPORATION (US) 1988-04-26 US disclosed
EP-0228416-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES. SCHERING CORP (US) 1987-07-15 EP disclosed
US-4680298-A Tricyclic anti-allergy and use as anti-inflammatory agents SCHERING CORPORATION (US) 1987-07-14 US disclosed
WO-1986007537-A2 PHARMACEUTICAL COMPOSITIONS CONTAINING AZANAPHTHALENES SCHERING CORPORATION (US) 1986-12-31 WO disclosed
EP-0127135-A2 Fused tricyclic derivatives of naphthyridinone and pyridone and the corresponding thiones SCHERING CORPORATION (US) 1984-12-05 EP disclosed